Xiao Qing Fan
Director/Board Member bei ZHEJIANG INT'L GROUP CO.,LTD.
Profil
Xiao Qing Fan is currently a Director at Zhejiang International Pharmaceutical Co., Ltd.
and a Member-Supervisory Board at Zhejiang Int'l Group Co., Ltd.
In terms of education, Mr. Fan received an undergraduate degree from Zhejiang University of Finance & Economics in 2004.
Aktive Positionen von Xiao Qing Fan
| Unternehmen | Position | Beginn |
|---|---|---|
| ZHEJIANG INT'L GROUP CO.,LTD. | Director/Board Member | 09.04.2021 |
Zhejiang International Pharmaceutical Co., Ltd.
 Zhejiang International Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Zhejiang Int' l Group Co., Ltd., Zhejiang International Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company that manufactures and distributes pharmaceutical products. The private company is based in Hangzhou, China. The company was founded in 1998. The CEO is Mi Yang. Zhejiang International Pharmaceutical Co. was acquired by Zhejiang Int'l Group Co., Ltd. on May 30, 2015 for $197.01 million. | Director/Board Member | - |
Ausbildung von Xiao Qing Fan
| Zhejiang University of Finance & Economics | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ZHEJIANG INT'L GROUP CO.,LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Zhejiang International Pharmaceutical Co., Ltd.
Zhejiang International Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Zhejiang Int' l Group Co., Ltd., Zhejiang International Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company that manufactures and distributes pharmaceutical products. The private company is based in Hangzhou, China. The company was founded in 1998. The CEO is Mi Yang. Zhejiang International Pharmaceutical Co. was acquired by Zhejiang Int'l Group Co., Ltd. on May 30, 2015 for $197.01 million. | Health Technology |
